Robert W. Baird downgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from an outperform rating to a neutral rating in a research note released on Friday morning, Marketbeat reports. The brokerage currently has $72.00 target price on the biotechnology company’s stock, down from their previous target price of $104.00. Several other brokerages have also […]
Evercore ISI began coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) in a research report report published on Tuesday, Marketbeat reports. The firm issued an outperform rating and a $113.00 price target on the biotechnology company’s stock. Several other equities research analysts have also recently issued reports on BMRN. Wells Fargo & Company […]
National Bank of Canada FI Cuts Stake in BioMarin Pharmaceutical Inc (NASDAQ:BMRN) dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.
Motley Fool Wealth Management LLC reduced its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 3.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 470,289 shares of the biotechnology company’s stock after selling 18,667 shares during the quarter. […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective decreased by Morgan Stanley from $115.00 to $112.00 in a research note released on Friday, Benzinga reports. Morgan Stanley currently has an overweight rating on the biotechnology company’s stock. Several other equities research analysts have also recently weighed in on the company. Cantor Fitzgerald reaffirmed […]